Cellectra™ Human CD19 NanoSort Microbeads, Research grade

Application Data

Superior CD19 positive-selected Cell Separation Performance (Comparison with Company M)
Separation performance was evaluated using samples containing 1×10⁷ human PBMCs, processed with CD19 microbeads from Acro, Company M at recommended dosages. Positive and negative fractions were collected, and 1×10⁶ cells from each fraction were immunostained with APC-Labeled anti-CD19 Antibody and 7-AAD, followed by flow cytometric analysis. Data indicated that Acro microbeads achieved a final purity of 98% (baseline: 17.32%), with a target cell residue of only 0.55% in the negative fraction. These findings validate outstanding separation performance, confirming an optimal balance of purity and recovery relative to competitor benchmarks.

Comparison of CD19 positive-selected Cell Separation Performances
Isolation efficacy was validated using samples containing 1×10⁷ human PBMCs processed with the recommended dosage of Cellectra™ Human CD19 NanoSort Microbeads, Research grade, in parallel with Company M. Comparative analysis demonstrated that Acro NanoSort Microbeads achieved higher cell recovery rates than both competitors, while purity and cell viability were comparable to Company M.

CD19 positive-selected Cell Separation Performances of Different Donors
The separation performances of human PBMCs exhibited minor inter-donor variability, yet consistently maintained high purity and cell recovery across all donors(Routinely tested).

CD19 positive-selected Cell Separation Performances after Freeze-Thawing and Accelerated Aging at 37℃
Freeze-thaw stability was verified by subjecting the microbeads to 3 cycles prior to separation testing. Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use).
Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles. Following 3.5 and 7-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.

Batch-to-Batch Consistency about CD19 positive-selected Cell Separation Performances.
Manufacturing reproducibility was verified by conjugating three batches of CD19 NanoSort Microbeads with two corresponding batches of synthesized magnetic beads. Performance testing for human PBMC separation was conducted without dose adjustment; final dosage optimization will be completed during the pre-launch phase. Data indicates that all batches achieved consistent high purity and recovery, establishing reliable batch-to-batch consistency.